Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules

Lipids in Health and Disease

Volumn 7, Issue , 2008, Pages

  Das, Undurti N ^a,b  

^a UND LIFE SCIENCES   (United States)

^b Bharati Vidyapeeth's Medical College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSINASE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CD59 ANTIGEN; DIHOMO GAMMA LINOLENIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; FOLIC ACID; GAMMA LINOLENIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LIPOXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROPROTECTIN D1; NITRIC OXIDE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN; PROSTAGLANDIN E1; PROSTAGLANDIN I3; RESOLVIN; TELOMERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; PROTECTIVE AGENT;

ADD ON THERAPY; ALZHEIMER DISEASE; ANTIARRHYTHMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; CHOLINERGIC SYSTEM; COGNITION; DEGRANULATION; DEPRESSION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; KIDNEY FUNCTION; LACTATION; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; NEUTROPHIL; NONHUMAN; PREGNANT WOMAN; RISK REDUCTION; SCHIZOPHRENIA; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TREATMENT DURATION; DIET THERAPY; METABOLISM; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; FATTY ACIDS, ESSENTIAL; HUMANS; PROTECTIVE AGENTS; STROKE;

EID: 55149091968     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-7-37     Document Type: Article

References (209)

1. Tobacco: global burden and community solutions. TF Pechacek S Asma MP Eriksen, Evidence based cardiology London: BMJ Books, Yusuf S, Calms A, Camm AJ, Fallen EL, Gersh BJ, 1998 165 178
2. Beta blockade during and after myocardial infarction: an overview of the randomised trials. S Yusuf R Peto J Lewis R Collins P Sleight, Prog Cardiovasc Dis 1985 27 335 371 10.1016/S0033-0620(85)80003-7 2858114
3. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists Collaboration, BMJ 2002 324 71 86 11786451 10.1136/bmj.324.7336.S71
4. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med 2000 342 145 153 10.1056/NEJM200001203420301 10639539
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Scandinavian Simvastatin Survival Study Group, Lancet 1994 344 1383 1399 10.1016/S0140- 6736(94)90566-5 7968073
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, N Engl J Med 1998 339 1349 1357 10.1056/NEJM199811053391902 9841303
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. FM Sacks MA Pfeffer LA Moye JL Rouleau JD Rutherford TG Cole L Brown JW Warnica JM Arnold CC Wun BR Davis E Braunwald, N Engl J Med 1996 336 1001 1009 10.1056/NEJM199610033351401
8. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. JF Plehn BR Davis FM Sacks JL Rouleau V Pfeffer TE Cuddy LA Moye LB Piller J Rutherford LM Simpson E Braunwald, Circulation 1999 99 216 223 9892586
9. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group, Lancet 2002 360 7 22 10.1016/S0140- 6736(02)09327-3 12114036
10. Two decades of progress in preventing vascular disease. S Yusuf, Lancet 2002 360 2 3 10.1016/S0140-6736(02)09358-3 12114031
11. A strategy to reduce cardiovascular disease by more than 80%. NJ Wald MR Law, BMJ 2003 326 1419 1423 12829553 10.1136/bmj.326.7404.1419
12. Effects of combinations of drugs on all mortality in patients with ischaemic heart disease: nested case-control analysis. J Hippisley-Cox C Coupland, BMJ 2005 330 1059 1063 15879390 10.1136/bmj.330.7499.1059
13. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. CH Hennekens FM Sacks A Tonkin J Jukema R Byington B Pitt DA Berry SM Berry NF Ford AJ Walker K Natarajan C Sheng-Lin FT Fiedorek R Belder, Arch Intern Med 2003 164 40 44 10.1001/archinte.164.1.40
14. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. L Wei S Ebrahim C Bartlett PD Davey FM Sullivan TM MacDonald, BMJ 2005 330 821 825 15790616 10.1136/bmj.38398.408032.8F
15. An update on aspirin in the primary prevention of cardiovascular disease. R Eidelman P Herbert S Weisman CH Hennekens, Arch Intern Med 2005 163 2006 2010 10.1001/archinte.163.17.2006
16. A randomised trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. PM Ridker N Cook I Lee D Gordon JM Gaziano JE Manson CH Hennekens JE Buring, N Engl J Med 2005 352 1293 1304 10.1056/NEJMoa050613 15753114
17. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. J Toole MR Malinow LE Chambless JD Spence LC Pettigrew VJ Howard EG Sides CH Wang M Stampfer, JAMA 2004 291 565 575 10.1001/jama.291.5.565 14762035
18. Essential fatty acids: Biochemistry, physiology, and pathology. UN Das, Biotechnology J 2006 1 420 439 10.1002/biot.200600012
19. Essential fatty acids. RH Lerman, Altern Ther Health Med 2006 12 20 29 16708767
20. Omega-6 and omega-3 essential fatty acids in atherosclerosis. DF Horrobin, Semin Thromb Hemost 1993 19 129 137 8356458
21. New biological and clinical roles for the n-6 and n-3 fatty acids. HS Hansen, Nutr Rev 1994 52 162 167 8052455
22. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. J Claria CN Serhan, Proc Natl Acad Sci USA 1995 92 9475 9479 7568157 10.1073/pnas.92.21.9475
23. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. N Chiang K Gronert CB Clish JA O'Brien MW Freeman CN Serhan, J Clin Invest 1999 104 309 316 10430612 10.1172/JCI7016
24. Lipid mediator class switching during acute inflammation signals in resolution. BD Levy CB Clish B Schmidt K Gronert CN Serhan, Nat Immunol 2001 2 612 619 10.1038/89759 11429545
25. 4 accelerate resolution of allergic edema in Angiostronglus costaricensis-infected rats: relationship with concurrent eosinophilia. C Bandeira-Melo MF Serra BI Diaz RSB Cordeiro PMR Silva HL Lenzi YS Bakhle CN Serhan MA Martins, J Immunol 2000 164 1029 1036 10623853
26. Resolvins and protectins in the termination program of acute inflammation. A Ariel CN Serhan, Trends Immunol 2007 28 176 183 10.1016/j.it.2007.02.007 17337246
27. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. BD Levy P Kohli K Gotlinger O Haworth S Hong S Kazani E Israel KJ Haley CN Serhan, J Immunol 2007 178 496 502 17182589
28. Regulation of mevalonate synthesis in low density lipoprotein receptor knockout mice fed n-3 or n-6 polyunsaturated fatty acids. A El-Sohemy MC Archer, Lipids 1999 34 1037 1043 10.1007/s11745-999-0455-8 10580331
29. Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentration in patients with hyperlipidemia. N Nakamura T Hamazaki H Jokaji S Minami M Kobayashi, Int J Clin Lab Res 1998 28 192 195 10.1007/s005990050043 9801932
30. Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin. RE Duncan A El-Sohemy MC Archer, Cancer Lett 2005 224 221 228 10.1016/j.canlet.2004.11.031 15914273
31. Regulation of mevalonate synthesis in rat mammary glands by dietary n-3 and n-6 polyunsaturated fatty acids. A El-El-Sohemy MC Archer, Cancer Res 1997 57 3685 3687 9288773
32. Statins stimulate arachidonic acid release and prostaglandin I2 production in rat liver cells. L Levine, Lipids Health Dis 2003 2 1 12689340 10.1186/1476-511X-2-1
33. Essential fatty acids as possible mediators of the actions of statins. UN Das, Prostaglandins Leukot Essen Fatty Acids 2001 65 37 40 10.1054/plef.2001. 0285
34. Statin-stimulated nitric oxide release from endothelium. LW Dobrucki L Kalinowski IT Dobrucki T Malinski, Med Sci Monit 2001 7 622 627 11433186
35. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. CC McGown ZL Brookes, Br J Anaesth 2007 98 163 175 10.1093/bja/ael358 17251210
36. Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Y Okuda K Kawashima T Sawada K Tsurumaru M Asano S Suzuki M Soma T Nakajima K Yamashita, Biochem Biophys Res Commun 1997 232 487 491 10.1006/bbrc.1997.6328 9125207
37. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. H Yasuda PS Yuen X Hu H Zhou RA Star, Kidney Int 2006 69 1535 1542 16557230 10.1038/sj.ki.5000300
38. Dietary fish oil n-3 fatty acids increase regulatory cytokine production and exert anti-inflammatory effects in two murine models of inflammation. S Sierra F Lara-Villoslada M Comalada M Olivares J Xaus, Lipids 2006 41 1115 1125 10.1007/s11745-006-5061-2 17269557
39. Nitric oxide activates cyclooxygenase enzymes. D Salvemini TP Misko JL Masferrer K Seibert MG Currie P Needleman, Proc Natl Acad Sci USA 1993 90 7240 7244 7688473 10.1073/pnas.90.15.7240
40. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. RS Rosenson, Atherosclerosis 2004 173 1 12 10.1016/S0021-9150(03) 00239-9 15177118
41. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. D Colquhoun A Keech D Hunt I Marschner J Simes P Glaziou H White P Barter A Tonkin LIPID Study Investigators, Eur Heart J 2004 25 771 777 10.1016/j.ehj.2004.03.013 15120888
42. Short-term Effects of Atorvastatin on Bone Turnover in Male Patients with Hypercholesterolemia. T Majima Y Komatsu A Fukao K Ninomiya T Matsumura K Nakao, Endocr J 2007 54 145 151 10.1507/endocrj.K06-127 17185879
43. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. M Briel M Studer TR Glass HC Bucher, Am J Med 2004 117 596 606 10.1016/j.amjmed.2004. 04.022 15465509
44. Statins prevent beta-amyloid inhibition of sympathetic alpha7-nAChR-mediated nitrergic neurogenic dilation in porcine basilar arteries. ML Si C Long DI Yang MF Chen TJ Lee, J Cereb Blood Flow Metab 2005 25 1573 1585 10.1038/sj.jcbfm.9600232 16192990
45. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. T Aprahamian R Bonegio J Rizzo H Perlman DJ Lefer IR Rifkin K Walsh, J Immunol 2006 177 3028 3034 16920939
46. Relation of plasma phospholipid and cholesterol ester fatty acid composition to carotid artery intima-media thickness: the Atherosclerosis Risk in Communities (ARIC) Study. J Ma AR Folsom L Lewis JH Eckfeldt, Am J Clin Nutr 1997 65 551 559 9022543
47. Dietary omega-3 fatty acid intake and cardiovascular risk. TL Psota SK Gebauer P Kris-Etherton, Am J Cardiol 2006 98 suppl 3i 18i 10.1016/j.amjcard. 2005.12.022
48. Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. WS Harris, Pharmacol Res 2007 55 217 223 17324586 10.1016/j.phrs.2007.01.013
49. A quantitative analysis of fish consumption and stroke risk. C Bouzan JT Cohen WE Connor PM Kris-Etherton GM Gray A Konig RS Lawrence DA Savitz SM Teusch, Am J Prev Med 2005 29 347 352 10.1016/j.amepre.2005.07.002 16242601
50. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. KN Green H Martinez-Coria H Khashwji EB Hall KA Yurko-Mauro L Ellis FM LaFerla, J Neurosci 2007 27 4385 4395 10.1523/JNEUROSCI.0055-07.2007 17442823
51. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. S Kotani E Sakaguchi S Warashina N Matsukawa Y Ishikura Y Kiso M Sakakibara T Yoshimoto J Guo T Yamashima, Neurosci Res 2006 56 159 164 10.1016/j.neures.2006.06.010 16905216
52. Dietary polyunsaturated fatty acids decrease anti-dsDNA and anti-cardiolipin antibodies production in idiotype induced mouse model of systemic lupus erythematosus. R Reifen M Blank A Afek Y Kopilowiz D Sklan ME Geshwin B German S Yoshida Y Shoenfeld, Lupus 1998 7 192 197 10.1191/096120398678919985 9607643
53. 4 generation provides a new mechanism for the immunomodulatory effects of statins and thiazolidinediones. BD Levy, Circulation 2006 114 873 875 10.1161/CIRCULATIONAHA.106.647925 16940203
54. Augmentation of myocardial production of 15-epi-lipoxin A4 by pioglitazone and atorvastatin in the rat. Y Birnbaum Y Ye Y Lin Freeberg SY SP Nishi JD Martinez MH Huang BF Uretsky JR Perez-Polo, Circulation 2006 114 929 935 10.1161/CIRCULATIONAHA.106.629907 16908763
55. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. A Nordoy KH Bonaa PM Sandset JB Hansen H Nilsen, Arterioscler Thromb Vasc Biol 2000 20 259 265 10634827
56. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. A Nordoy JB Hansen J Brox B Svensson, Nutr Metab Cardiovasc Dis 2001 11 7 16 11383326
57. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. A Nordoy B Svensson JB Hansen, J Thromb Haemost 2003 1 690 697 10.1046/j.1538-7836.2003.00140.x 12871402
58. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease. A Nordoy, Minerva Med 2002 93 357 363 12410168
59. Long-chain polyunsaturated fatty acids in Chinese and Swedish mothers: diet, breast milk and infant growth. M Xiang LS Harbige R Zetterstrom, Acta Paediatr 2005 94 1543 1549 10.1080/08035250500251601 16303692
60. Low arachidonic acid rather than alpha-tocopherol is responsible for the delayed postnatal development in offspring of rats fed fish oil instead of olive oil during pregnancy and lactation. E Amusquivar FJ Ruperez C Barbas E Herrera, J Nutr 2000 130 2855 2865 11053532
61. Visual, cognitive, and language assessments at 39 months: a follow-up study of children fed formulas containing long-chain polyunsaturated fatty acids to 1 year of age. N Auestad DT Scott JS Janowsky C Jacobsen RE Carroll MB Montalto R Halter W Qiu JR Jacobs WE Connor SL Connor JA Taylor M Neuringer KM Fitzgerald RT Hall, Pediatrics 2003 112 3 Pt 1 e177 183 10.1542/peds.112.3.e177 12949309
62. A Docosahexaenoic acid-functional food during pregnancy benefits infant visual acuity at four but not six months of age. MP Judge O Harel CJ Lammi-Keefe, Lipids 2007 42 117 122 10.1007/s11745-006-3007-3 17393217
63. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. IB Helland L Smith K Saarem OD Saugstad CA Drevon, Pediatrics 2003 111 e39 e44 10.1542/peds.111.1.e39 12509593
64. Similar effects on infants of n-3 and n-6 fatty acids supplementation to pregnant and lactating women. IB Helland OD Saugstad L Smith K Saarem K Solvoll T Ganes CA Drevon, Pediatrics 2001 108 E82 10.1542/peds.108.5.e82 11694666
65. Cognitive assessment at 21/2 years following fish oil supplementation in pregnancy: a randomized controlled trial. JA Dunstan K Simmer G Dixon SL Prescott, Arch Dis Child Fetal Neonatal Ed 2006 93 F45 F50 10.1136/adc.2006. 099085 17185423
66. Maternal fish oil supplementation in lactation: effect on developmental outcome in breast-fed infants. L Lauritzen MH Jorgensen SF Olsen EM Straarup KF Michaelsen, Reprod Nutr Dev 2005 45 535 547 10.1051/rnd:2005044 16188206
67. Growth and development in term infants fed long-chain polyunsaturated fatty acids: a double-masked, randomized, parallel, prospective, multivariate study. N Auestad R Halter RT Hall M Blatter ML Bogle W Burks JR Erickson KM Fitzgerald V Dobson SM Innis LT Singer MB Montalto JR Jacobs W Qiu MH Bernstein, Pediatrics 2001 108 372 381 10.1542/peds.108.2.372 11483802
68. Supplementation of fish-oil and soy-oil during pregnancy and psychomotor development of infants. F Tofail I Kabir JD Hamadani F Chowdhury S Yesmin F Mehreen SN Huda, J Health Popul Nutr 2006 24 48 56 16796150
69. Alpha-linolenic acid supplementation during human pregnancy does not effect cognitive functioning. RH de Groot J Adam J Jolles Hornstra, Prostaglandins Leukot Essent Fatty Acids 2004 70 41 47 10.1016/j.plefa.2003.08. 004 14643178
70. Evidence for the presence of angiotensins in normal, unstimulated alveolar macrophages and monocytes. B Dezso J Jacobson K Poulsen, J Hypertens 1989 7 1 5 11 2708812
71. An inhibitory effect of dietary polyunsaturated fatty acids on renin secretion in the isolated perfused rat kidney. JP Codde KD Croft A Barden E Mathews R Vandongen LJ Beilin, J Hypertens 1984 2 265 270 6397528
72. The effect of dietary supplementation with linoleic and gammalinolenic acids on the pressor response to angiotensin II - a possible role in pregnancy-induced hypertension? PM O'Brien R Morrison F Broughton Pipkin, Br J Clin Pharmacol 1985 19 335 342 2985102
73. Evening primrose oil, a dietary prostaglandin precursor, diminishes vascular reactivity to renin and angiotensin II in rats. BA Scholkens D Gehring V Schlotte U Weithmann, Prostaglandins Leukot Med 1982 8 273 285 10.1016/0262-1746(82)90050-6 7043495
74. Antihypertensive properties of linoleic acid and fish oil omega-3 fatty acids independent of the prostaglandin system. R Hui J St-Louis P Falardeau, Am J Hypertens 1989 2 610 617 2550031
75. Inhibition of renin by plasma linoleic acid. RT Talwalkar TA Kotchen, Am J Med Sci 1988 296 3 192 197 10.1097/00000441-198809000-00008 3052059
76. In vitro and in vivo inhibition of renin by fatty acids. TA Kotchen WJ Welch RT Talwalkar, Am J Physiol 1978 234 E593 E599 665762
77. Effect of linoleic acid infusion on blood pressure in normotensive and hypertensive rats. SR Reddy R Talwalkar J Downs TA Kotchen, Am J Physiol 1989 257 2 Pt 2 H611 H617 2764141
78. Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro. UN Das, Proc Soc Exp Biol Med 1997 214 374 379 9111529
79. Eicosapentaenoic acid modifies lipid composition in caveolae and induces translocation of endothelial nitric oxide synthase. Q Li Q Zhang M Wang S Zhao J Ma N Luo N Li Y Li G Xu J Li, Biochimie 2007 89 169 177 10.1016/j.biochi.2006. 10.009 17125900
80. 5 desaturases may be a factor in the initiation and progression of atherosclerosis. UN Das, Prostaglandins Leukot Essen Fatty Acids 2007 76 251 268 10.1016/j.plefa.2007.03.001
81. P450-dependent arachidonic acid metabolism and angiotensin-II-induced renal damage. E Kaergel DN Muller H Honeck J Theuer E Shagdarsuren A Mullally FC Luft W-H Schunck, Hypertension 2002 40 273 279 10.1161/01.HYP.0000029240.44253. 5E 12215466
82. Does elevated nitric oxide production enhance the release of prostacyclin from shear stressed aortic endothelial cells? W Wang SL Diamond, Biochem Biophys Res Commun 1997 233 748 751 10.1006/bbrc.1997.6548 9168926
83. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration, BMJ 2002 324 71 86 11786451 10.1136/bmj.324.7336.S71
84. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. DM Schreinemachers RB Everson, Epidemiology 1994 5 138 146 10.1097/00001648-199403000-00003 8172988
85. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. J Claria CN Serhan, Proc Natl Acad Sci USA 1995 92 9475 9479 7568157 10.1073/pnas.92.21.9475
86. Cardiovascular effects of n-3 fatty acids. A Leaf PC Weber, N Engl J Med 1988 322 697 698
87. Dietary supplementation with n-3 polyunsaturated fatty acids and human platelet function: a review with particular emphasis on implications for cardiovascular disease. SD Kristensen EB Schmidt J Dyerberg, J Intern Med Suppl 1989 731 141 150 2650690
88. Fish oil preparations rich in docosahexaenoic acid modify platelet responsiveness to prostaglandin-endoperoxide/thromboxane A2 receptor agonists. M Scheurlen M Kirchner MR Clemens K Jaschonek, Biochem Pharmacol 1993 46 245 249 10.1016/0006-2952(93)90410-X 8347146
89. Dietary omega-3 fatty acid intake and cardiovascular risk. TL Psota SK Gebauer P Kris-Etherton, Am J Cardiol 2006 98 suppl 3i 18i 10.1016/j.amjcard. 2005.12.022
90. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. MH Davidson, Am J Cardiol 2006 98 suppl 27i 33i 10.1016/j.amjcard.2005. 12.024
91. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. JG Robinson NJ Stone, Am J Cardiol 2006 98 suppl 39i 49i 10.1016/j.amjcard.2005. 12.026
92. Antiarrhythmic effects of omega-3 fatty acids. JA Reiffel A McDonald, Am J Cardiol 2006 98 suppl 50i 60i 10.1016/j.amjcard.2005.12.027
93. Secondary prevention of coronary heart disease with omega-3 fatty acids. TA Jacobson, Am J Cardiol 2006 98 suppl 61i 70i 10.1016/j.amjcard.2005.12.028
94. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? UN Das, Prostaglandins Leukot Essen Fatty Acids 2000 63 351 362 10.1054/plef.2000.0226
95. The role of prostaglandins in the antiarrhythmic effect of ischemic preconditioning. L Wang, J Biomed Sci 2001 8 406 410 10.1007/BF02255949 11549882
96. Prostacyclin as an endogenous anti-arrhythmic agent. UN Das, Basic Res Cardiol 1983 78 716 718 10.1007/BF01907219 6362651
97. Prostaglandin E1: electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil Investigators. JC Somberg V Yelamanchi J Molnar M Aschermann PJ Bernik A Caspi A Marmor B Rabinowitz L Reisin W Ruzyllo, Am J Ther 1997 4 401 414 10423637
98. Tissue omega-6/omega-3 fatty acid ratio and risk for coronary artery disease. WS Harris B Assaad WC Poston, Am J Cardiol 2006 98 suppl 19i 26i 10.1016/j.amjcard.2005.12.023
99. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. D Mozaffarian A Ascherio FB Hu MJ Stampfer WC Willett DS Siscovick EB Rimm, Circulation 2005 111 166 173 10.1161/01.CIR. 0000152099.87287.83
100. Linoleic and eicosapentaenoic acids in adipose tissue and platelets and risk of coronary heart disease. DA Wood RA Riemersma S Butler M Thomson C Macintyre RA Elton MF Oliver, Lancet 1987 i 177 183 10.1016/S0140-6736(87)90001- 8
101. Adipose tissue and platelet fatty acids and coronary heart disease in Scottish men. DA Wood S Butler RA Riemersma M Thomson MF Oliver M Fulton A Birtwhistle R Elton, Lancet 1984 ii 117 121 10.1016/S0140-6736(84)91044-4
102. Linoleic acid and risk of sudden cardiac death. TL Roberts DA Wood RA Riemersma PJ Gallagher FC Lampe, Br Heart J 1993 70 524 529 8280516 10.1136/hrt.70.6.524
103. Fatty acid composition in total phospholipids of human coronary arteries in sudden cardiac death. R Luostarinen M Boberg T Saldeen, Atherosclerosis 1993 99 187 193 10.1016/0021-9150(93)90021-L 8503947
104. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. CV Felton D Crook MJ Davies MF Oliver, Arterioscler Thromb Vasc Biol 1997 17 1337 1345 9261265
105. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. F Thies JM Garry P Yaqoob K Rerkasem J Williams CP Shearman PJ Gallagher PC Calder RF Grimble, Lancet 2003 361 477 485 10.1016/S0140-6736(03)12468-3 12583947
106. Dihomo-gamma-linolenic acid increases the metabolism of eicosapentaenoic acid in perfused vascular tissue. H Juan W Sametz, Prostaglandins Leukotrienes Med 1985 19 79 86 10.1016/0262-1746(85)90162-3
107. The relevance of prostaglandins in human hypertension. MJ Dunn HJ Grone, Adv Prostaglandin Thromboxane Leukot Res 1985 13 179 87 3159200
108. Hydroperoxides produced by n-6 lipoxygenation of arachidonic and linoleic acids potentiate synthesis of prostacyclin related compounds. JC Bordet M Guichardant M Lagarde, Biochim Biophys Acta 1988 958 460 468 3124885
109. 3) production from eicosapentaenoic acid in human endothelial cells. JC Bordet M Guichardant M Lagarde, Biochem Biophys Res Commun 1986 135 403 410 10.1016/0006-291X(86)90009-4 3008717
110. Oestrogen, statins and essential fatty acids: Similarity in their actions and benefits-is there a common link? UN Das, Nutrition 2002 18 178 188 10.1016/S0899-9007(01)00719-5 11844650
111. Effects of diet and simvastatin on fatty acid composition in hypercholesterolemic men: a randomized controlled trial. A Jula J Marniemi T Ronnemaa A Virtanen R Huupponen, Arterioscler Thromb Vasc Biol 2005 25 1952 1959 10.1161/01.ATV.0000177812.84927.fa 16020749
112. Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. JI Harris JR Hibbeln RH Mackey MF Muldoon, Prostaglandins Leukot Essent Fatty Acids 2004 71 263 269 10.1016/j.plefa.2004. 06.001 15310527
113. Effect of simvastatin on the uptake and metabolic conversion of palmitic, dihomo-gamma-linoleic and alpha-linolenic acids in A549 cells. MJ Bellini MP Polo MJ de Alaniz MG de Bravo, Prostaglandins Leukot Essent Fatty Acids 2003 69 351 367 10.1016/S0952-3278(03)00149-2 14580370
114. Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. P Rise F Pazzucconi CR Sirtori C Galli, Nutr Metab Cardiovasc Dis 2001 11 88 94 11434193
115. New perspectives on aspirin and the endogenous control of acute inflammatory resolution. T Morris M Stables DW Gilroy, ScientificWorldJournal 2006 6 1048 1065 10.1100/tsw.2006.192 16951898
116. Lipoxins and new lipid mediators in the resolution of inflammation. JM Schwab CN Serhan, Curr Opin Pharmacol 2006 6 414 420 10.1016/j.coph.2006.02.006 16750421
117. Novel omega-3-derived local mediators in anti-inflammation and resolution. CN Serhan, Pharmacol Ther 2005 105 7 21 10.1016/j.pharmthera.2004. 09.002 15626453
118. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. E Lopez-Garcia MB Schultze JE Manson JB Meigs CM Albert N Rifai WC Willett FB Hu, J Nutr 2004 134 1806 1811 15226473
119. IL-10 expression is involved in the regulation of the immune response by omega 3 fatty acids. S Sierra F Lara-Villoslada M Olivares J Junenez J Boza J Xaus, Nutr Hosp 2004 19 376 382 15672655
120. Effect of prostaglandins and their precursors on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and various interleukins. GS Kumar UN Das, Prostaglandins Leukot Essent Fatty Acids 1994 50 331 334 10.1016/0952-3278(94)90242-9 7938085
121. Effects of n-3 fatty acids on renal function and renal prostaglandin E metabolism. R Dusing A Struck BO Gobel B Weisser H Vetter, Kidney Int 1990 38 315 319 10.1038/ki.1990.202 2402124
122. High linoleic acid diets ameliorate diabetic nephropathy in rats. UO Barcelli M Weiss D Beach A Motz B Thompson, Am J Kidney Dis 1990 16 244 251 2399916
123. N-6 and N-3 PUFA in liver lipids, thromboxane formation and blood pressure from SHR during diets supplemented with evening primrose, sunflower seed or fish oil. P Singer I Berger V Moritz D Forster C Taube, Prostaglandins Leukot Essen Fatty Acids 1990 39 207 211 10.1016/0952-3278(90)90073-T
124. Interrelationships between salt and fish oil in stroke-prone spontaneously hypertensive rat. T Vaskonen J Laakso E Mervaala E Sievi H Karppanen, Blood Press 1996 5 178 189 10.3109/08037059609062127 8790929
125. Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. JP Grande HJ Walker BJ Holub GM Warner DM Keller JD Haugen JV Donadio Jr TP Dousa, Kidney Int 2000 57 1027 1040 10.1046/j.1523-1755.2000. 00930.x 10720955
126. The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. JV Donadio JP Grande, Semin Nephrol 2004 24 225 243 10.1016/j.semnephrol.2004.01.004 15156528
127. The effects of dietary supplementation with fish oil on renal function in cyclosporine-treated renal transplant recipients. JJ Homan van der Heide HJ Bilo AM Tegzess AJ Donker, Transplantation 1990 49 523 527 10.1097/00007890- 199003000-00010 2316014
128. Chronic effects of omega-3 fatty acids (fish oil) in a rat 5/6 renal ablation model. WF Clark A Parbtani DJ Philbrick BJ Holub MW Huff, J Am Soc Nephrol 1991 1 1343 1353 1912396
129. Effects of flaxseed and flax oil diets in a rat-5/6 renal ablation model. AJ Ingram A Parbtani WF Clark E Spanner MW Huff DJ Philbrick BJ Holub, Am J Kidney Dis 1995 25 320 329 10.1016/0272-6386(95)90015-2 7847360
130. Resolvin D series and protectin D1 mitigate acute kidney injury. JS Duffield S Hong VS Vaidya Y Lu G Fredman CN Serhan JV Bonventre, J Immunol 2006 177 5902 5911 17056514
131. Furosemide enhances the release of endothelial kinins, nitric oxide and prostacyclin. G Wiemer E Fink W Linz M Hropot BE Scholkens P Wohlfart, J Pharmacol Exp Ther 1994 271 1611 1615 7996475
132. Cyclooxygenase-2 nd the renal renin-angiotensin system. RC Harris MZ Zhang HF Cheng, Acta Physiol Scand 2004 181 543 547 10.1111/j.1365-201X.2004. 01329.x 15283769
133. n-3 polyunsaturated fatty acids, heart rate variability and ventricular arrhythmias in post-AMI-patients. A clinical controlled trial. JH Christensen P Gustenhoff E Korup J Aaroe E Toft JM Moller K Rasmussen J Dyerberg EB Schmidt, Ugeskr Laeger 1997 159 5525 5529 9312922
134. Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids. JH Christensen MS Christensen J Dyerberg EB Schmidt, Am J Clin Nutr 1999 70 331 337 10479194
135. Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. M Minami S Kimura T Endo N Hamaue M Hirafuji H Togashi M Yoshioka H Saito S Watanabe T Kobayashi H Okuyama, Pharmacol Biochem Behav 1997 58 1123 1129 10.1016/S0091-3057(97)00300-6 9408223
136. Cholinergic stimulation of arachidonic acid and phosphatidic acid metabolism in C62B glioma cells. JJ DeGeorge P Morell KD McCarthy EG Lapetina, J Biol Chem 1986 261 3428 3433 3081504
137. Facilitation by arachidonic acid of acetylcholine release from the rat hippocampus. T Almeida RA Cunha JA Ribeiro, Brain Res 1999 826 104 111 10.1016/S0006-8993(99)01267-6 10216201
138. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. LV Borovikova S Ivanova M Zhang H Yang GI Botchkina LR Watkins H Wang N Abumrad JW Eaton KJ Tracey, Nature 2000 405 458 462 10.1038/35013070 10839541
139. Pharmacological stimulation of the cholinergic antiinflammatory pathway. TR Bernik SG Friedman M Ochani R DiRaimo L Ulloa H Yang S Sudan CJ Czura SM Ivanova CJ Tracey, J Exp Med 2002 195 781 788 11901203 10.1084/jem.20011714
140. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. H Wang M Yu M Ochani CA Amella M Tanovic S Susaria JH Li H Wang H Yang L Ulloa Y Al-Abed CJ Czura KJ Tracey, Nature 2003 421 384 388 10.1038/nature01339 12508119
141. Folic acid administration increases N-3 polyunsaturated fatty acids in rat plasma and tissue lipids. ML Pita MJ Delgado, Thromb Haemost 2000 84 420 423 11019965
142. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. P Durand M Prost D Blache, Atherosclerosis 1996 121 231 243 10.1016/0021-9150(95)06724-8 9125297
143. Folic acid says NO to vascular diseases. UN Das, Nutrition 2003 19 686 692 10.1016/S0899-9007(02)01044-4 12831960
144. Differential effects of fish oil and folic acid supplementation during pregnancy in rats on cognitive performance and serum glucose in their offspring. S Joshi S Rao S Girigosavi M Daware A Kale M Hegde, Nutrition 2004 20 465 472 10.1016/j.nut.2004.01.012 15105035
145. Maternal folic acid supplementation to dams on marginal protein level alters brain fatty acid levels of their adult offspring. S Rao S Joshi A Kale M Hegde S Mahadik, Metabolism 2006 55 628 634 10.1016/j.metabol.2005.12.008 16631439
146. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. GG Rhoads CL Gulbrandsen A Kagan, N Engl J Med 1976 294 293 298 173994
147. Delayed catabolism of high density lipoprotein apolipoprotein A-I and A-II in human cholesteryl ester transfer protein deficiency. K Ikewaki DJ Rader T Sakamoto M Nishiwaki N Wakimoto JR Schaefer T Ishikawa T Fairwell LA Zech H Nakamura M Nagano HB Brewer, J Clin Invest 1993 92 1650 1658 8408618 10.1172/JCI116750
148. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. PJ Barter HB Brewer Jr MJ Chapman CH Hennekens DJ Rader AR Tall, Arterioscler Thromb Vasc Biol 2003 23 160 167 10.1161/01.ATV.0000054658.91146.64 12588754
149. Cholesteryl ester transfer protein and atherosclerosis. I Inazu J Koizumi H Mabuchi, Curr Opin Lipidol 2000 11 389 396 10.1097/00041433-200008000-00008 10945721
150. The yin and yang of cholesteryl ester transfer protein and atherosclerosis. GF Watts, Clin Sci 2002 103 595 597 12444912
151. Low-fat and high-monounsaturated fatty acid diets decrease plasma cholesterol ester transfer protein concentrations in young, healthy, normolipemic men. S Jansen J Lopez-Miranda P Castro F Lopez-Segura C Marin JM Ordovas E Paz J Jimenez-Pereperez F Fuentes F Perez-Jimenez, Am J Clin Nutr 2000 72 36 41 10871558
152. Regulation by long-chain fatty acids of the expression of cholesteryl ester transfer protein in HepG2 cells. R Hirano O Igarashi K Kondo H Itakura A Matsumoto, Lipids 2001 36 401 406 10.1007/s11745-001-0735-3 11383693
153. Modulation of plasma cholesteryl ester transfer protein activity by unsaturated fatty acids in Tunisian type 2 diabetic women. M Smaoui S Hammami N Attia R Chaaba N Abid N Kilani H Kchaou S Mahjoub M Abid M Hammami, Nutr Metab Cardiovasc Dis 2006 16 44 53 10.1016/j.numecd.2005.05.011 16399491
154. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. JJP Kastelein AI van Leuven L Burgess GW Evans JA Kuivenhoven PJ Barter JH Revkin DE Grobbee WA Riley CL Shear WT Duggan ML Bots for the RADIANCE 1 Investigators, N Engl J Med 2007 356 1620 1630 10.1056/NEJMoa071359 17387131
155. Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis. SE Nissen JC Tardif SJ Nicholls JH Revkin CL Shear WT Duggan W Ruzyllo WB Bachinsky GP Lasala EM Tuzcu for the ILLUSTRATE Investigators, N Engl J Med 2007 356 1304 1316 10.1056/NEJMoa070635 17387129
156. Fish oils and cardiovascular disease. BNC Prichard CCT Smith KLE Ling DJ Betteridge, BMJ 1995 310 819 820 7711611
157. Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases. Y Kagawa M Nishizawa M Suzuki, J Nutr Sci Vitaminol (Tokyo) 1982 28 441 453 7175583
158. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. D Kromhout EB Bosschieter C de Lezenne Coulander, N Engl J Med 1985 312 1205 1209 3990713
159. n-3 fatty acids and 5-y risks of death and cardiovascular disease events in patients with coronary artery disease. AT Erkkila S Lehto K Pyorala MI Uusitupa, Am J Clin Nutr 2003 78 65 71 12816772
160. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. K He Y Song ML Daviglus K Liu L Van Horn AR Dyer P Greenland, Circulation 2004 109 2705 2711 10.1161/01.CIR.0000132503.19410.6B 15184295
161. Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males: an 8 weeks dietary intervention study. J Dyerberg DC Eskesen PW Andersen A Astrup B Buermann JH Christensen P Clausen BF Rasmussen EB Schmidt T Tholstrup, Eur J Clin Nutr 2004 58 1062 1070 10.1038/sj.ejcn.1601934 15220949
162. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. FB Hu LL Bronner WC Willett MJ Stampfer KM Rexrode CM Albert D Hunter JE Manson, JAMA 2002 287 1815 1821 10.1001/jama.287.14.1815 11939867
163. Fish consumption and the 30-year risk of fatal myocardial infarction. ML Daviglus J Stamler AJ Orencia AR Dyer K Liu P Greenland MK Walsh D Morris RB Shekelle, N Engl J Med 1997 336 1046 1053 10.1056/NEJM199704103361502 9091800
164. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. HC Bucher P Hengstler C Schindler G Meier, Am J Med 2002 112 298 304 10.1016/S0002-9343(01)01114-7 11893369
165. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. GISSI Prevenzione Investigators, Lancet 1999 354 447 455 10.1016/S0140-6736(99)07072-5 10465168
166. Effects of eicosapentaenoic acid (EPA) on major coronary events in hypercholesterolemic patients (JELIS): a randomized open-label blinded endpoint analysis. M Yokoyama H Origasa M Matsuzaki, Lancet 2007 369 1090 1098 10.1016/S0140-6736(07)60527-3 17398308
167. Prostaglandins and pacemaker activity in isolated guinea pig SA node. KR Courtney WT Colwell RA Jensen, Prostaglandins 1978 16 451 459 10.1016/0090-6980(78)90224-1 725077
168. Cardiac pacemaking, cardiac glycosides, anti-arrhythmic drugs and prostaglandins. UN Das, Speculations Sci Tech 1979 2 381 384
169. 2+ exchange in isolated myocardial muscle cells. UN Das AM Lee GJ Barritt, Prostaglandins Leukot Med 1983 12 305 314 10.1016/0262-1746(83)90009-4 6361781
170. Prostacyclin as an endogenous anti-arrhythmic agent. UN Das, Basic Res Cardiol 1983 78 716 718 10.1007/BF01907219 6362651
171. Influence of dietary fish oil on mitochondrial function and response to ischemia. JB McMillin RJ Bick CR Benedict, Am J Physiol 1992 263 5 Pt 2 H1479 485 1332513
172. Influence of the phospholipid n-6/n-3 polyunsaturated fatty acid ratio on the mitochondrial oxidative metabolism before and after myocardial ischemia. L Demaison JP Sergiel D Moreau A Grynberg, Biochim Biophys Acta 1994 1227 53 59 7918684
173. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. JX Kang A Leaf, Proc Natl Acad Sci USA 1994 91 9886 9890 7937911 10.1073/pnas.91.21.9886
174. Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes. JX Kang A Leaf, Eur J Pharmacol 1996 297 97 106 10.1016/0014-2999(95) 00701-6 8851173
175. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. YF Xiao JX Kang JP Morgan A Leaf, Proc Natl Acad Sci USA 1995 92 11000 11004 7479925 10.1073/pnas.92.24.11000
176. Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells. YF Xiao Q Ke Y Chen JP Morgan A Leaf, Biochem Biophys Res Commun 2004 321 116 123 10.1016/j.bbrc.2004.06.114 15358223
177. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. SW Brouilette JS Moore AD McMahon JR Thompson I Ford J Shepherd CJ Packard NJ Samani for the West of Scotland Coronary Prevention Study Group, Lancet 2007 369 107 114 10.1016/S0140-6736(07)60071-3 17223473
178. Telomere shortening of peripheral blood mononuclear cells in coronary disease patients with metabolic disorders. N Obana S Takagi Y Kinouchi Y Takita A Sekikawa S Takahashi N Hiwatashi S Oikawa T Shimosegawa, Intern Med 2003 42 150 153 10.2169/internalmedicine.42.150 12636233
179. Telomere attrition in white blood cell correlating with cardiovascular damage. H Nakashima R Ozono C Suyama T Sueda M Kambe T Oshima, Hypertens Res 2004 27 319 325 10.1291/hypres.27.319 15198478
180. Shortened telomere length in white blood cells of patients with IDDM. E Jeanclos A Krolewski J Skurnick M Kimura H Aviv JH Warram A Aviv, Diabetes 1998 47 482 486 10.2337/diabetes.47.3.482 9519758
181. Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes. MJ Sampson MS Winterborne JC Hughes N Dozio DA Hughes, Diabetes Care 2006 29 283 289 10.2337/diacare.29.02.06.dc05-1715 16443874
182. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. A Benetos JP Gardner M Zureik C Labat L Xiaobin C Adampoulos M Temmar KE Bean F Thomas A Aviv, Hypertension 2004 43 182 185 10.1161/01.HYP.0000113081.42868.f4 14732735
183. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. S Demissie D Levy EJ Benjamin LA Cupples JP Gardner A Herbert M Kimura MG Larson JB Meigs JF Keaney A Aviv, Aging Cell 2006 5 325 330 10.1111/j.1474-9726.2006.00224.x 16913878
184. Rise in insulin resistance is associated with escalated telomere attrition. JP Gardner S Li SR Srinivasan W Chen M Kimura X Lu GS Berenson A Aviv, Circulation 2006 111 2171 2177 10.1161/01.CIR.0000163550.70487.0B
185. Nitric oxide activates telomerase and delays endothelial cell senescence. M Vasa K Breitschopf AM Zeiher S Dimmeler, Circ Res 2000 87 540 542 11009557
186. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. T Hayashi H Matsui-Hirai A Miyazaki-Akita A Fukatsu J Funami QF Ding S Kamalanathan Y Hattori LJ Ignarro A Iguchi, Proc Natl Acad Sci USA 2006 103 17018 17023 17075048 10.1073/pnas.0607873103
187. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence. F Scalera J Borlak B Beckmann J Martens-Lobenhoffer T Thum M Tager SM Bode-Boger, Arterioscler Thromb Vasc Biol 2004 24 1816 1822 10.1161/01.ATV.0000141843.77133.fc 15308550
188. Asymmetric dimethylarginine (ADMA) accelerates cell senescence. SM Bode-Boger F Scalera J Martens-Lobenhoffer, Vasc Med 2005 10 Suppl 1 S65 S71 10.1191/1358863x05vm606oa 16444871
189. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. T Minamino H Miyauchi T Yoshida Y Ishida H Yoshida I Komuro, Circulation 2002 105 1541 1544 10.1161/01.CIR.0000013836.85741.17 11927518
190. eNOS activity is reduced in senescent human endothelial cells: Preservation by hTERT immortalization. H Matsushita E Chang AJ Glassford JP Cooke CP Chiu PS Sao, Circ Res 2001 89 793 798 10.1161/hh2101.098443 11679409
191. Beneficial actions of polyunsaturated fatty acids in cardiovascular diseases: But, how and why? UN Das, Current Nutr Food Sci 2008 4 2 31 10.2174/157340108783497418
192. Polyunsaturated fatty acids inhibit telomerase activity in DLD-1 human colorectal adenocarcinoma cells: a dual mechanism approach. T Eitsuka K Nakagawa T Suzuki T Miyazawa, Biochim Biophys Acta 2005 1737 1 10 16216547
193. Dual mechanisms for telomerase inhibition in DLD-1 human colorectal adenocarcinoma cells by polyunsaturated fatty acids. T Eitsuka K Nakagawa T Miyazawa, Biofactors 2004 21 19 21 15630164
194. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. TA Mori RJ Woodman V Burke IB Puddey KD Croft LJ Beilin, Free Radic Biol Med 2003 35 772 781 10.1016/S0891-5849(03)00407-6 14583341
195. Effect of omega 3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary F2-isoprostane excretion. TA Mori IB Puddey V Burke KD Croft DW Dunstan JH Rivera LJ Beilin, Redox Rep 2000 5 45 46 10905544
196. Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy. A Barden TA Mori JA Dunstan AL Taylor CA Thornton KD Croft LJ Beilin SL Prescott, Free Radic Res 2004 38 233 239 10.1080/ 10715760310001656722 15129731
197. Phagocyte-derived catecholamines enhance acute inflammatory injury. MA Flier D Rittirsch BA Nadeau AJ Chen JV Sarma FS Zetoune SR McGuire RP List DE Day LM Hoesel H Gao N Van Rooijen MS Huber-Lang RR Neubig PA Ward, Nature 2007 449 721 726 10.1038/nature06185 17914358
198. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. KM Appleton RC Hayward G Gunnell TJ Peters PJ Rogers D Kessler AR Ness, Am J Clin Nutr 2006 84 1308 1316 17158410
199. Omega-3 fatty acids in major depressive disorder: A preliminary double-blind, placebo-controlled trial. KP Su SY Huang CC Chiu WW Shen, Eur Neuropscychopharmacol 2003 13 267 271 10.1016/S0924-977X(03)00032-4
200. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. BK Puri BR Leavitt MR Hayden CA Ross A Rosenblatt JT Greenamyre S Hersch KS Vaddadi A Sword DF Horrobin M Manku H Murck, Neurology 2005 65 286 292 10.1212/01.wnl.0000169025.09670.6d 16043801
201. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. M Arvindakshan M Ghate PK Ranjekar DR Evans SP Mahadik, Schizophr Res 2003 62 195 204 10.1016/S0920-9964(02)00284-0 12837515
202. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. KN Green H Martinez-Coria H Khashwji EB Hall KA Yurko-Mauro L Ellis FM LaFerla, J Neurosci 2007 27 4385 4395 10.1523/JNEUROSCI.0055-07.2007 17442823
203. Can perinatal supplementation of long-chain polyunsaturated fatty acids prevent atopy, bronchial asthma and other inflammatory conditions? UN Das, Med Sci Monit 2006 12 RA99 RA111 16733498
204. Can perinatal supplementation of long-chain polyunsaturated fatty acids prevents schizophrenia in adult life? UN Das, Med Sci Monit 2004 10 HY33 HY37 15567990
205. Perinatal supplementation of long-chain polyunsaturated fatty acids, immune response, and adult diseases. UN Das, Med Sci Monit 2004 10 HY19 HY25 15114276
206. Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease? UN Das, Lipids Health Dis 2008 7 19 18489792 10.1186/1476-511X-7-19
207. Can essential fatty acids reduce the burden of disease(s)? UN Das, Lipids Health Dis 2008 7 9 18348729 10.1186/1476-511X-7-9
208. 5 desaturases may be a factor predisposing to the development of insulin resistance syndrome. UN Das, Prostaglandins Leukotrienes Essen Fatty Acids 2005 72 343 350 10.1016/j.plefa.2005.01.002
209. Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer's disease - but how and why? UN Das, Prostaglandins Leukot Essent Fatty Acids 2008 78 11 19 10.1016/j.plefa. 2007.10.006 18054217